Journal of the Formosan Medical Association (Sep 2022)

Gender differences in clinical characteristics of emergency department patients involving illicit drugs use with analytical confirmation

  • Te- I. Weng,
  • Lian-Yu Chen,
  • Hsien-Yi Chen,
  • Jiun-Hao Yu,
  • Yu-Jang Su,
  • Sung-Wei Liu,
  • Derek K. Tracy,
  • Yen-Chia Chen,
  • Chih-Chuan Lin,
  • Cheng-Chung Fang

Journal volume & issue
Vol. 121, no. 9
pp. 1832 – 1840

Abstract

Read online

Background: To compare gender differences in socio-demographics, clinical manifestations, and laboratory test results of individuals who visited emergency departments (EDs) involving drug use. Methods: We retrospectively collected the data from 10 hospitals in Taiwan on drug-related ED visits from May 2017 to December 2020. We then examined the gender differences in their socio-demographics, clinical manifestations, urine toxicological results, and other laboratory tests results using chi-square or multivariable logistic regression. Results: Among individuals with drug-related ED visits, there were 546 (73.7%) men and 195 (26.3%) women. The most commonly used drugs were meth/amphetamine, followed by synthetic cathinones, and ketamine and its analogs. Compared to men, women were younger (32.03 ± 10.86 vs. 36.51 ± 10.84 years, p < 0.001) and more likely to use new psychoactive substances (NPS) (p = 0.011). Men were more likely to have human immunodeficiency virus infection (p < 0.001), whereas women were more likely to report psychiatric comorbidities (p = 0.003). Women were less likely to have aggressive behaviors (odds ratio (OR): 0.59, 95% CI: 0.39–0.88). After adjusting for socio-demographics and drug types, women were still less likely to have aggressive behaviors than men (adjusted OR: 0.59, 95% CI: 0.38–0.93). The likelihood of rhabdomyolysis and intensive care unit admission was higher in men (p < 0.001). Conclusion: We found considerable gender differences in clinical characteristics among ED-visiting drug users, which could offer valuable information for the future development of more tailored gender-specific drug prevention and treatment strategies.

Keywords